BACKGROUND: To determine if the intervention of individual advice improves adherence and effectiveness to highly active antiretroviral therapy. METHODS: Randomized open trial. Patients treated with zidovudine + lamivudine + indinavir were assigned (2/1) to conventional care or individual advise. Individual advise consists in adaptation to treatment to patient style of live and detailed information of therapy. Adherence were estimated with structured interview and pillo counts and were considered correct when more than 90% of prescribed drugs were taken. RESULTS:Patients 170, conventional care: 110 and IA: 60. FOLLOW-UP: 24 weeks. Baseline characteristics were similar in both groups. Correct adherence were estimated in 52.7% of conventional care and in 76.7% of individual advise (p = 0.002, relative risk: 1.45; CI 95%: 1.16-1.82). Undetectable viral load (NASBA < 50 copies/ml) in 54.5% of conventional care and in 65% of individual advise (p = 0.18, relative risk: 1.19; CI 95%: 0.93-1.53). Reduction of viral load in the conventional care group 1.02 +/- 0.5 log10/ml, and in the individual advise group 1.98 +/- 0.7 log10/ml. CONCLUSION: The individual advice improve adherence with a tendency to improve effectiveness of highly active antiretroviral therapy.
RCT Entities:
BACKGROUND: To determine if the intervention of individual advice improves adherence and effectiveness to highly active antiretroviral therapy. METHODS: Randomized open trial. Patients treated with zidovudine + lamivudine + indinavir were assigned (2/1) to conventional care or individual advise. Individual advise consists in adaptation to treatment to patient style of live and detailed information of therapy. Adherence were estimated with structured interview and pillo counts and were considered correct when more than 90% of prescribed drugs were taken. RESULTS:Patients 170, conventional care: 110 and IA: 60. FOLLOW-UP: 24 weeks. Baseline characteristics were similar in both groups. Correct adherence were estimated in 52.7% of conventional care and in 76.7% of individual advise (p = 0.002, relative risk: 1.45; CI 95%: 1.16-1.82). Undetectable viral load (NASBA < 50 copies/ml) in 54.5% of conventional care and in 65% of individual advise (p = 0.18, relative risk: 1.19; CI 95%: 0.93-1.53). Reduction of viral load in the conventional care group 1.02 +/- 0.5 log10/ml, and in the individual advise group 1.98 +/- 0.7 log10/ml. CONCLUSION: The individual advice improve adherence with a tendency to improve effectiveness of highly active antiretroviral therapy.
Authors: Lawrence Mbuagbaw; Bhairavi Sivaramalingam; Tamara Navarro; Nicholas Hobson; Arun Keepanasseril; Nancy J Wilczynski; R Brian Haynes Journal: AIDS Patient Care STDS Date: 2015-03-31 Impact factor: 5.078
Authors: Melanie A Thompson; Michael J Mugavero; K Rivet Amico; Victoria A Cargill; Larry W Chang; Robert Gross; Catherine Orrell; Frederick L Altice; David R Bangsberg; John G Bartlett; Curt G Beckwith; Nadia Dowshen; Christopher M Gordon; Tim Horn; Princy Kumar; James D Scott; Michael J Stirratt; Robert H Remien; Jane M Simoni; Jean B Nachega Journal: Ann Intern Med Date: 2012-03-05 Impact factor: 25.391
Authors: Jessica E Hart; Christie Y Jeon; Louise C Ivers; Heidi L Behforouz; Adolfo Caldas; Peter C Drobac; Sonya S Shin Journal: J Acquir Immune Defic Syndr Date: 2010-06 Impact factor: 3.731
Authors: Jane M Simoni; Cynthia R Pearson; David W Pantalone; Gary Marks; Nicole Crepaz Journal: J Acquir Immune Defic Syndr Date: 2006-12-01 Impact factor: 3.731
Authors: Amadou Jallow; Sofia Kälvemark Sporrong; Lilian Walther-Jallow; Peter M Persson; Urban Hellgren; Orjan Ericsson Journal: Pharm World Sci Date: 2007-02-27
Authors: Cynthia R Pearson; Mark A Micek; Jane M Simoni; Peter D Hoff; Eduardo Matediana; Diane P Martin; Stephen S Gloyd Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731